Literature DB >> 23328787

CD30+ lymphomatoid drug reactions.

Melissa P Pulitzer1, Katherine A Nolan, Robin G Oshman, Robert G Phelps.   

Abstract

We report 5 cases of cutaneous CD30+ lymphomatoid drug reactions that occurred shortly after the onset of drug exposure and resolved promptly upon withdrawal of the offending agents. The cases showed protean dermatologic manifestations ranging from diffuse erythema with desquamation to macules, papules, and annular plaques. The suspect drugs were amlodipine (a calcium channel blocker) for 2 cases, sertraline (a selective serotonin reuptake inhibitor) for 1 case, gabapentin for 1 case, and levofloxacin (a fluoroquinolone) versus cefepime (a fourth generation cephalosporin), and metoprolol (a beta blocker), in the fifth case. The histopathologic findings included varying combinations of spongiotic dermatitis, lichenoid infiltrates, and interface dermatitis with a dermal infiltrate of large atypical lymphocytes. Three of the 5 cases contained as much as 30% CD30+ staining of all lymphocytes, whereas the remaining 2 showed 5%-15% positivity. Three patients had a history of allergy or immune dysregulation. Increased knowledge of CD30 positivity in lymphomatoid drug reactions may be relevant in an era of targeted drug therapies. Recognition of these findings may help clinicians to tailor appropriate clinical evaluation and treatment including a review of medications and the removal of possible offending agents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23328787     DOI: 10.1097/DAD.0b013e31826bc1e5

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  5 in total

1.  Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

Authors:  Madeleine Duvic; Lauren C Pinter-Brown; Francine M Foss; Lubomir Sokol; Jeffrey L Jorgensen; Pramoda Challagundla; Karen M Dwyer; Xiaoping Zhang; Michael R Kurman; Rocco Ballerini; Li Liu; Youn H Kim
Journal:  Blood       Date:  2015-01-20       Impact factor: 22.113

2.  Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study.

Authors:  Teresa Grieco; Patrizia Maddalena; Alvise Sernicola; Rovena Muharremi; Stefania Basili; Domenico Alvaro; Roberto Cangemi; Alfredo Rossi; Giovanni Pellacani
Journal:  Dermatol Ther       Date:  2021-10-13       Impact factor: 3.858

3.  Multifocal and recurrent cutaneous pseudolymphoma associated with lamotrigine and review of the literature.

Authors:  Soroush Kazemi; Elanee Simmons; Maija Kiuru; Danielle M Tartar
Journal:  JAAD Case Rep       Date:  2022-08-10

4.  Amlodipine-induced hypersensitivity reaction mimicking CD30(+) mycosis fungoides.

Authors:  Ashley Gochoco; Elizabeth Jones; Christine Soutendijk; Onder Alpdogan; Wenyin Shi; Joya Sahu
Journal:  JAAD Case Rep       Date:  2016-08-17

5.  CD30+ lymphomatoid skin toxicity secondary to ipilimumab.

Authors:  Amelia E Bush; Andres Garcia; Janet Li; Jonathan Curry; Susan Y Chon
Journal:  JAAD Case Rep       Date:  2020-03-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.